MX2023006733A - Composiciones de peptidos y metodos para dominios de union anti-cd3. - Google Patents

Composiciones de peptidos y metodos para dominios de union anti-cd3.

Info

Publication number
MX2023006733A
MX2023006733A MX2023006733A MX2023006733A MX2023006733A MX 2023006733 A MX2023006733 A MX 2023006733A MX 2023006733 A MX2023006733 A MX 2023006733A MX 2023006733 A MX2023006733 A MX 2023006733A MX 2023006733 A MX2023006733 A MX 2023006733A
Authority
MX
Mexico
Prior art keywords
methods
binding domains
peptide compositions
peptide
polypeptide
Prior art date
Application number
MX2023006733A
Other languages
English (en)
Spanish (es)
Inventor
David Campbell
Thomas R Diraimondo
Original Assignee
Janux Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janux Therapeutics Inc filed Critical Janux Therapeutics Inc
Publication of MX2023006733A publication Critical patent/MX2023006733A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023006733A 2020-12-08 2021-12-07 Composiciones de peptidos y metodos para dominios de union anti-cd3. MX2023006733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063122820P 2020-12-08 2020-12-08
PCT/US2021/062233 WO2022125562A1 (en) 2020-12-08 2021-12-07 Peptide compositions and methods for anti-cd3 binding domains

Publications (1)

Publication Number Publication Date
MX2023006733A true MX2023006733A (es) 2023-08-14

Family

ID=81973732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006733A MX2023006733A (es) 2020-12-08 2021-12-07 Composiciones de peptidos y metodos para dominios de union anti-cd3.

Country Status (9)

Country Link
US (1) US20240043536A1 (enExample)
EP (1) EP4259177A4 (enExample)
JP (1) JP2024500335A (enExample)
KR (1) KR20230137301A (enExample)
CN (1) CN116981682A (enExample)
AU (1) AU2021396507A1 (enExample)
CA (1) CA3201401A1 (enExample)
MX (1) MX2023006733A (enExample)
WO (1) WO2022125562A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR125758A1 (es) 2020-04-04 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
EP4615514A2 (en) * 2022-11-10 2025-09-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
WO2026002279A1 (en) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Mask peptide, cleavable substrate, multispecific antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014974A2 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US11046745B2 (en) * 2015-07-14 2021-06-29 BioNTech SE Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof
AR125758A1 (es) * 2020-04-04 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
CA3196726A1 (en) * 2020-10-30 2022-05-05 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
TW202237653A (zh) * 2020-12-09 2022-10-01 美商詹努克斯治療有限公司 與經腫瘤活化之靶定trop2及效應細胞抗原之抗體相關之組合物及方法
EP4259193A4 (en) * 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens

Also Published As

Publication number Publication date
CN116981682A (zh) 2023-10-31
CA3201401A1 (en) 2022-06-16
KR20230137301A (ko) 2023-10-04
EP4259177A4 (en) 2024-11-06
AU2021396507A1 (en) 2023-07-06
US20240043536A1 (en) 2024-02-08
WO2022125562A1 (en) 2022-06-16
JP2024500335A (ja) 2024-01-09
EP4259177A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
US12291724B2 (en) Tumor-infiltrating lymphocytes for adoptive cell therapy
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
MX2025008340A (es) Anticuerpos humanizados contra c-kit
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
MY159815A (en) Notch1 receptor binding agents and methods of use thereof
MY160662A (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
WO2007145840A3 (en) Compositions and methods for diagnosing and treating cancer
MX2010002053A (es) Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento.
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
SA520420109B1 (ar) أجسام مضادة
MEP7408A (xx) Peptidi koji sprečavaju vezivanje igg za fcrn
MX2022005850A (es) Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
ZA202211303B (en) Anti- muc1-sea antibodies
WO2008031016A3 (en) Heterocyclic ligands for integrin imaging and therapy
NZ602515A (en) Proteins that bind pi16 and uses thereof
IL168646A (en) Antibodies binding to human magic roundabout (mr) and uses thereof for inhibition of angiogenesis
ZA202305642B (en) Anti-tspan8/anti-cd3 bispecific antibody and anti-tspan8 antibody
MX2024015502A (es) Anticuerpos variantes que se unen a los receptores de linfocitos t gamma-delta
Syed et al. Angiostatin receptor annexin II in vascular tumors including angiosarcoma
Huo et al. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma
MX2025007872A (es) Anticuerpos anti-il-18bp
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
MX2024011776A (es) Proteínas anti-cd3 y anti-pd-l1 biespecíficas activables y usos de las mismas
ATE480552T1 (de) Stq-peptide